Natco Fights Back After Charges Of Marketing Substandard Albupax Drug; Says Test Kits Yielding Varying Results
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Controversy over the charges leveled by India's drug controller on Natco Pharma for allegedly selling substandard anti-cancer drug Albupax thickened as the Hyderabad-headquartered company openly blamed competition for "resorting to an insidious campaign through selective leaks and half-truths to malign its image and reputation.
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).